Phase 1 Type 1 Diabetes Trial, Recruiting (NCT07242664)

Phase 1 Type 1 Diabetes Trial, Recruiting NCT07242664 Sponsor: Gan and Lee Pharmaceuticals, USA Condition: Type 1 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT07242664 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 1 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have had type 1 diabetes for at least 12 months
People aged between 18 and 64 years old
People whose HbA1c (a measure of average blood sugar levels over roughly 3 months) is 9.0% or below
People whose Body Mass Index (BMI) falls between 18.5 and 29.0
People who have been on a stable insulin dose for at least 2 months, with that dose falling within a specific range based on body weight (confirm with trial site)

Who may not be able to join:

People whose blood pressure falls outside the ranges of 90–140 (top number) or 50–99 (bottom number) mmHg
People who have other significant ongoing health conditions
People who have had more than one severe low blood sugar episode — meaning one that required help from another person — in the 180 days before the screening visit
People who cannot feel the warning signs when their blood sugar drops too low (sometimes called hypoglycemia unawareness)
People whose kidneys are not functioning above a certain level, based on a test called eGFR (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 14 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +49 (0) 2131 4018 409

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07242664

Sponsor: Gan and Lee Pharmaceuticals, USA

Phase: Phase 1

Status: Recruiting

Condition: Type 1 Diabetes

Trial contact: +49 (0) 2131 4018 409

More information: https://clinicaltrials.gov/study/NCT07242664

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have had type 1 diabetes for at least 12 months
People aged between 18 and 64 years old
People whose HbA1c (a measure of average blood sugar levels over roughly 3 months) is 9.0% or below
People whose Body Mass Index (BMI) falls between 18.5 and 29.0
People who have been on a stable insulin dose for at least 2 months, with that dose falling within a specific range based on body weight (confirm with trial site)

Who may not be able to join:

People whose blood pressure falls outside the ranges of 90–140 (top number) or 50–99 (bottom number) mmHg
People who have other significant ongoing health conditions
People who have had more than one severe low blood sugar episode — meaning one that required help from another person — in the 180 days before the screening visit
People who cannot feel the warning signs when their blood sugar drops too low (sometimes called hypoglycemia unawareness)
People whose kidneys are not functioning above a certain level, based on a test called eGFR (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Gan and Lee Pharmaceuticals, USA

Registry

ClinicalTrials.gov

Start date

13 October 2025

Est. completion

28 February 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

the relative potency of GZR33 to insulin degludec

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov